Multiple lines of evidence suggest the involvement of the IGF-1/insulin pathways across a range of malignancies, including both NSCLC and small cell lung cancer (SCLC) [14-17], and inhibition of IGF-1 signaling pathway is a potential therapy for human lung cancer [18]. Here, INS is linked to small cell lung carcinoma.